2. Signaling Pathways
  3. PROTAC
  4. PROTACs
  5. PROTACs Modulator

PROTACs Modulator

PROTACs Isoform Comparison

PROTACs Modulators (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-139682A
    Dovitinib-RIBOTAC TFA 2759351-69-2 98.35%
    Dovitinib RIBOTAC TFA is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC TFA can inhibit the metastasis of breast cancer and has anti-tumor activity.
    Dovitinib-RIBOTAC TFA
  • HY-139682
    Dovitinib-RIBOTAC 2759351-68-1 99.31%
    Dovitinib RIBOTAC is an RNA-targeting RIBOTAC degrader that can specifically bind to and degrade pre-miR-21. Dovitinib RIBOTAC can inhibit the metastasis of breast cancer and has anti-tumor activity.
    Dovitinib-RIBOTAC
  • HY-142662
    PROTAC IRAK3 degrader-1 2712600-00-3
    PROTAC IRAK3 degrade-1 (compound 23) is a potent and selective degrader of IRAK3 (IC50 = 5 nM).
    PROTAC IRAK3 degrader-1
  • HY-141878
    di-Ellipticine-RIBOTAC 2767983-76-4
    Di-Ellipticine-RIBOTAC (Compound 7) is a RNA RIBOTAC degrader, capable of specifically binding and degrading r(G4C2)exp. Di-Ellipticine-RIBOTAC only cuts the expanded GGGGCC repeat RNA in the pathogenic factor of amyotrophic lateral sclerosis/ frontotemporal dementia (c9ALS/FTD) - the chromosome 9 open reading frame 72 (9orf72) gene (r(G4C2)exp), and has no effect on normal short repetitive sequences. Di-Ellipticine-RIBOTAC significantly improves the pathological phenotype of c9ALS/FTD in cells and mouse models. Di-Ellipticine-RIBOTAC can be used for the study of c9ALS/FTD.
    di-Ellipticine-RIBOTAC